AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Medicover

Declaration of Voting Results & Voting Rights Announcements Nov 28, 2025

2943_rns_2025-11-28_38ec4a64-45a3-4f48-92f3-26c3d0abb85d.pdf

Declaration of Voting Results & Voting Rights Announcements

Open in Viewer

Opens in native device viewer

PRESS RELEASE Stockholm, 28 November 2025 10:00:00 CET

NUMBER OF SHARES AND VOTES IN MEDICOVER

The number of shares and votes in Medicover AB (publ) ("Medicover") has changed as a result of conversions of in total 73,625 class A shares into B shares carried out in November following requests from shareholders in accordance with the conversion clause in Medicover's articles of association.

Today, the last trading day of the month, there are in total 153,535,195 shares in Medicover, of which 76,549,801 are class A shares, together carrying 76,549,801 votes, 74,428,717 are class B shares, together carrying 7,442,871.7 votes and 2,556,677 are class C shares, together carrying 255,667.7 votes. The total number of votes in Medicover is 84,248,340.4.

For further information, please contact:

Hanna Bjellquist, Head of Investor Relations

+46 703 033 272

[email protected]

Medicover is a leading international healthcare and diagnostic services company and was founded in 1995. Medicover operates a large number of ambulatory clinics, hospitals, specialty-care facilities, laboratories and blood-drawing points and the largest markets are Poland, Germany, Romania and India. In 2024, Medicover had revenue of €2,092 million and more than 47,000 employees. For more information, go to www.medicover.com

This information is information that Medicover AB (Publ) is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2025-11-28 10:00 CET.

Talk to a Data Expert

Have a question? We'll get back to you promptly.